Techno Medica Co., Ltd. (JP:6678)
:6678
6678 Stock Chart & Stats
¥2245.00
-¥13.00(-0.72%)
At close: 4:00 PM EST
¥2245.00
-¥13.00(-0.72%)
Day’s Range― - ―
52-Week Range¥1,580.00 - ¥2,787.00
Previous CloseN/A
Volume3.70K
Average Volume (3M)5.40K
Market Cap
¥20.79B
Enterprise Value¥7.41B
Total Cash (Recent Filing)¥8.67B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)15.1
Beta0.58
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.02%
Share Statistics
EPS (TTM)37.13
Shares Outstanding8,760,000
10 Day Avg. Volume4,730
30 Day Avg. Volume5,400
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)0.84
Price to Sales (P/S)1.23
P/FCF Ratio12.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet Strength (zero Debt)Zero debt materially lowers financial risk and provides durable financial flexibility. Over a 2–6 month horizon this supports resilient operations, ability to fund capex, R&D or dividends without refinancing, and greater capacity to withstand cyclical weakness or pursue strategic bolt-on investments.
Stable Gross MarginsConsistent ~49–50% gross margins indicate persistent product pricing power and cost structure stability in in‑vitro diagnostics. Durable gross margins protect operating profit against modest revenue swings, enabling ongoing reinvestment in consumables, product support and long-lived competitive advantages.
Strong Free Cash Flow ConversionHigh free cash flow conversion (near 1x of net income) supports earnings quality and internal funding capacity. Over time this underpins sustainable dividends, maintenance capex and selective growth investments without adding leverage, reinforcing long‑term financial resilience.
Bears Say
Revenue Decline In FY2025A nearly 4% revenue decline signals emerging demand weakness or market share pressure. If this trend persists it constrains scale benefits, limits ability to invest in R&D and commercial expansion, and can weaken long-term top-line growth prospects in a competitive med‑tech market.
Margin Compression (net Margin)A material drop in net margin reduces earnings power and free cash generation. Persistent margin erosion—from ~13.1% to ~10.1%—raises sensitivity to cost inflation or unfavorable mix, limiting capacity to fund growth and lowering return on invested capital over a multi‑month horizon.
Volatile Free Cash Flow GrowthIntermittent FCF volatility undermines predictability of cash available for dividends, buybacks or expansion. Even with strong conversion in some years, uneven operating cash relative to revenue complicates planning and increases execution risk for strategic investments over the medium term.
Techno Medica Co., Ltd. News
6678 FAQ
What was Techno Medica Co., Ltd.’s price range in the past 12 months?
Techno Medica Co., Ltd. lowest stock price was ¥1580.00 and its highest was ¥2787.00 in the past 12 months.
What is Techno Medica Co., Ltd.’s market cap?
Techno Medica Co., Ltd.’s market cap is ¥20.79B.
When is Techno Medica Co., Ltd.’s upcoming earnings report date?
Techno Medica Co., Ltd.’s upcoming earnings report date is May 13, 2026 which is in 43 days.
How were Techno Medica Co., Ltd.’s earnings last quarter?
Techno Medica Co., Ltd. released its earnings results on Feb 04, 2026. The company reported ¥37.13 earnings per share for the quarter, beating the consensus estimate of N/A by ¥37.13.
Is Techno Medica Co., Ltd. overvalued?
According to Wall Street analysts Techno Medica Co., Ltd.’s price is currently Overvalued.
Does Techno Medica Co., Ltd. pay dividends?
Techno Medica Co., Ltd. pays a Annually dividend of ¥68 which represents an annual dividend yield of 3.02%. See more information on Techno Medica Co., Ltd. dividends here
What is Techno Medica Co., Ltd.’s EPS estimate?
Techno Medica Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Techno Medica Co., Ltd. have?
Techno Medica Co., Ltd. has 8,760,000 shares outstanding.
What happened to Techno Medica Co., Ltd.’s price movement after its last earnings report?
Techno Medica Co., Ltd. reported an EPS of ¥37.13 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.143%.
Which hedge fund is a major shareholder of Techno Medica Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6678
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Techno Medica Co., Ltd.
Techno Medica Co., Ltd. engages in the research and development, manufacture, sale, import, and export of in-vitro diagnostic analyzers in Japan. The company offers test tube preparation, automatic urine aliquot, RFID specimen management, and RFID blood transfusion management, as well as blood gas, electrolyte, Erythrocyte Sedimentation Rate, nutrient, sugar and acid, and urine chemistry analyzers; electronic medical charts and pre-analytical instruments; and consumables and after sales services. Techno Medica Co., Ltd. was incorporated in 1987 and is headquartered in Yokohama, Japan.
Technical Analysis
PHC Holdings Corp.
―
Eiken Chemical Co., Ltd.
―
Nihon Kohden Corporation
―
Japan Medical Dynamic Marketing, Inc.
―
Koken Ltd.
―
Options Prices
Currently, No data available
---